oxaprozin has been researched along with Heart Failure in 2 studies
Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.
oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "12 patients aged 26-71 years with stable, compensated congestive heart failure (CHF) and 12 healthy controls matched for age, sex, height, weight, and serum albumin, received a 1200-mg oral dose of the nonsteroidal antiinflammatory agent 4,5-diphenyl-2-oxazolepropionic acid (oxaprozin)." | 7.67 | Oxaprozin pharmacokinetics in patients with congestive heart failure. ( Greenblatt, DJ; Knüchel, M; Ochs, HR, 1986) |
| "12 patients aged 26-71 years with stable, compensated congestive heart failure (CHF) and 12 healthy controls matched for age, sex, height, weight, and serum albumin, received a 1200-mg oral dose of the nonsteroidal antiinflammatory agent 4,5-diphenyl-2-oxazolepropionic acid (oxaprozin)." | 3.67 | Oxaprozin pharmacokinetics in patients with congestive heart failure. ( Greenblatt, DJ; Knüchel, M; Ochs, HR, 1986) |
| "Oxaprozin is a nonsteroidal anti-inflammatory drug which reaches peak plasma concentrations 2 to 6 hours after oral administration." | 2.40 | Clinical pharmacokinetics of oxaprozin. ( Davies, NM, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davies, NM | 1 |
| Ochs, HR | 1 |
| Greenblatt, DJ | 1 |
| Knüchel, M | 1 |
1 review available for oxaprozin and Heart Failure
| Article | Year |
|---|---|
Clinical pharmacokinetics of oxaprozin.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Interac | 1998 |
1 other study available for oxaprozin and Heart Failure
| Article | Year |
|---|---|
Oxaprozin pharmacokinetics in patients with congestive heart failure.
Topics: Adult; Aged; Female; Heart Failure; Humans; Kinetics; Male; Middle Aged; Oxaprozin; Propionates | 1986 |